These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 8485716

  • 1. Phase I study of amonafide dosing based on acetylator phenotype.
    Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB.
    Cancer Res; 1993 May 15; 53(10 Suppl):2304-8. PubMed ID: 8485716
    [Abstract] [Full Text] [Related]

  • 2. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
    Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M.
    Pharmacogenetics; 1996 Feb 15; 6(1):93-101. PubMed ID: 8845865
    [Abstract] [Full Text] [Related]

  • 3. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP.
    Clin Cancer Res; 1995 Jul 15; 1(7):699-704. PubMed ID: 9816035
    [Abstract] [Full Text] [Related]

  • 4. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
    Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J.
    Clin Pharmacol Ther; 1991 Nov 15; 50(5 Pt 1):573-9. PubMed ID: 1934870
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
    Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL.
    J Clin Oncol; 1995 Mar 15; 13(3):741-7. PubMed ID: 7884434
    [Abstract] [Full Text] [Related]

  • 6. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M.
    Cancer Res; 1991 Feb 01; 51(3):935-8. PubMed ID: 1988134
    [Abstract] [Full Text] [Related]

  • 7. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
    Leaf AN, Neuberg D, Schwartz EL, Wadler S, Ritch PS, Dutcher JP, Adams GL.
    Invest New Drugs; 1997 Feb 01; 15(2):165-72. PubMed ID: 9220297
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
    Felder TB, McLean MA, Vestal ML, Lu K, Farquhar D, Legha SS, Shah R, Newman RA.
    Drug Metab Dispos; 1987 Feb 01; 15(6):773-8. PubMed ID: 2893701
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical investigation of benzisoquinolinedione.
    Legha SS, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH.
    Cancer Treat Rep; 1987 Dec 01; 71(12):1165-9. PubMed ID: 3690526
    [Abstract] [Full Text] [Related]

  • 10. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 01; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical investigation of amonafide.
    Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ.
    J Clin Oncol; 1989 Sep 01; 7(9):1351-8. PubMed ID: 2549205
    [Abstract] [Full Text] [Related]

  • 12. Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
    Ratain MJ, Staubus AE, Schilsky RL, Malspeis L.
    Cancer Res; 1988 Jul 15; 48(14):4127-30. PubMed ID: 3383202
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
    Berger MZ, Kris MG, Gralla RJ, Marks LD, Potanovich LM, Dimaggio JJ, Heelan RT.
    Am J Clin Oncol; 1991 Apr 15; 14(2):124-6. PubMed ID: 1851387
    [Abstract] [Full Text] [Related]

  • 14. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
    Innocenti F, Iyer L, Ratain MJ.
    Drug Metab Dispos; 2001 Apr 15; 29(4 Pt 2):596-600. PubMed ID: 11259359
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic characterization of mitonafide in man.
    Brode E, Poveda Velasco A, Díaz-Rubio E, Rosell Costa R, Benavides Fissure A.
    Methods Find Exp Clin Pharmacol; 1992 Mar 15; 14(2):131-40. PubMed ID: 1598025
    [Abstract] [Full Text] [Related]

  • 16. Studies about the oral bioavailability of mitonafide and 2HCl amonafide, two new cytotoxic molecules.
    Torres Suárez AI, Camacho Sánchez MA.
    Farmaco; 1992 Apr 15; 47(4):497-508. PubMed ID: 1388597
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
    Malviya VK, Liu PY, O'Toole R, Alberts DS, Surwit E, Rosenoff S, Ward JH, Yu A, O'Sullivan J, Craig JB.
    Am J Clin Oncol; 1994 Feb 15; 17(1):37-40. PubMed ID: 8311005
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.